Pegcetacoplan for Lenvatinib-Associated Thrombotic Microangiopathy (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO1252; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Initial management included eculizumab therapy. To our knowledge, this represents one of the first reports describing the use of pegcetacoplan for refractory drug induced TMA. The marked reduction in proteinuria following treatment suggests a potential therapeutic role for proximal complement inhibition in selected cases of secondary TMAs."
Complement-mediated Rare Disorders • Fibrosis • Glomerulonephritis • Hypertension • Immunology • Nephrology • Renal Disease • Solid Tumor • Thyroid Gland Carcinoma
|
|
Krishna Mohita Kuruvada; Ming Wu; Kenar D. Jhaveri
|